TEMPORAL REGULATION OF TYPE III CRISPR-CAS EFFECTOR COMPLEX ACTIVITY

Irmantas Mogila1, Brighton Samatanga2, Ralf Seidel2, Virginijus Siksnys1, Gintautas Tamulaitis1

1 Institute of Biotechnology, Life Sciences Center, Vilnius University, Lithuania

2 Institute of Experimental Physics I, University of Leipzig, Germany

CRISPR-Cas is a unique defence system providing bacteria and archaea with adaptive immunity against viruses and foreign plasmids [1]. Short CRISPR RNA (crRNA) molecules assemble with Cas proteins to form effector complexes which monitor for foreign nucleic acids and destroy them. CRISPR-Cas employ variety of effector complexes which differ greatly in composition and interference mechanisms. Type III CRISPR-Cas systems utilize multisubunit Csm and Cmr complexes which bind crRNR complementary foreign transcripts and degrade them [2]. Upon complex binding to target RNA the Cas10 subunit is activated. This induce Cas10 DNA nucleolytic activity for invading DNA degradation and polymerase-cyclase activity for signalling molecule synthesis for altruistic suicide pathway [3, 4, 5, 6]. Since Cas10 activity could result in imprudent host nucleic acid degradation, it must be temporally regulated. Indeed, although bound RNA is fully cleaved in several seconds, the induced Cas10 activities slowly diminish over an hour [4, 6]. We hypothesized that RNA cleavage products stimulate the Cas10 protein of Type III effectors until they dissociate.

Therefore the aim of this study was to determine the rate of RNA cleavage products dissociation from Streptococcus thermophilus Csm complex (StCsm). To evaluate dissociation dynamics we used biochemical assay and fluorescence cross-correlation spectroscopy (FCCS), which allows the quantitative analysis of fluorescently labelled molecules co-diffusion in the sample [7]. Our data show that during cleavage reaction 5'- and 3'-products of activating RNA dissociate gradually with half-time of ~10-20 minutes, thus supporting our hypothesis.


[1] E. V. Koonin, K. S. Makarova, F. Zhang, Diversity, classification and evolution of CRISPR-Cas systems. Current Opinion in Microbiology 37, 67–78 (2017).

[2] G. Tamulaitis, M. Kazlauskiene, E. Manakova, Č. Venclovas, A. O. Nwokeoji, M. J. Dickman, P. Horvath, V. Siksnys, Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus, Mol Cell 56, 506-517, (2014).

[3] G. Tamulaitis, Č. Venclovas, V. Siksnys, Type III CRISPR-Cas Immunity: Major Differences Brushed Aside. Trends Microbiol. 25, 49–61 (2017).

[4] M. Kazlauskiene, G. Kostiuk, Č. Venclovas, G. Tamulaitis, V. Siksnys, A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. Science 357, 605–609 (2017).

[5] O. Niewoehner, C. Garcia-Doval, J. T. Rostøl et al. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers. Nature 548, 543–548 (2017).

[6] M. Kazlauskiene, G. Tamulaitis, G. Kostiuk, Č. Venclovas, V. Siksnys. Spatiotemporal Control of Type III-A CRISPR-Cas Immunity: Coupling DNA Degradation with the Target RNA Recognition. Mol Cell 62, 295–306, (2016).

[7] K. Bacia, S. A. Kim, P. Schwille, Fluorescence cross-correlation spectroscopy in living cells. Nat. Methods 3, 83–89 (2006).